Good News Is Balm for Gilead

Recs

6

Gilead Sciences (Nasdaq: GILD) got some good news Feb. 28. That day, the company found out that the results of a study sponsored by the National Institutes of Health (NIH) had confirmed that its Truvada HIV combo drug outperformed GlaxoSmithKline's (NYSE: GSK) Epzicom compound.

Part of the phase 4 NIH combo comparison study of Gilead's Truvada versus Glaxo's Epzicom was stopped early because patients taking the Glaxo drug were faring worse than patients on other therapies. NIH researchers stated, "Treatment combinations that included [Glaxo's Epzicom] were not as effective in controlling the virus as those on regimens containing [Gilead's Truvada]."

Shares of Gilead were up 4% Friday on news of the study results. It sure feels good to be proven right about a drugmaker like Gilead. The additional backing from the NIH for its HIV therapies undoubtedly provides even more of a shield against some of the new, second-line therapies and other front-line drugs making inroads against Gilead's top front-line HIV combination drugs.

As I've said before, the fact that Gilead's HIV combo drugs are entrenched as the standard of care provides a moat of sorts against other HIV treatments -- for example, from Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) -- because their drugs will probably have to show superiority and not just non-inferiority in order to knock Gilead's compounds off their No. 1 perch. That's a competitive advantage that just can't be overlooked, and that's why I like Gilead as an investment.

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 589859, ~/Articles/ArticleHandler.aspx, 11/9/2009 8:52:32 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Which Companies Can Buy It Like Buffett?

Related Tickers

11/6/2009 4:01 PM
GSK $40.52 Up +0.06 +0.15%
GlaxoSmithKline pl… CAPS Rating: *****
JNJ $60.30 Up +0.32 +0.53%
Johnson & Johnson CAPS Rating: *****
MRK $32.59 Down -0.12 -0.37%
Merck & Co., Inc. CAPS Rating: ****
GILD $46.26 Up +0.76 +1.67%
Gilead Sciences, I… CAPS Rating: *****

Community: Investing Wiki

Term Of The Hour

Accounts receivable: Accounts receivable is money that a customer owes to a company for goods or services sold on credit.

Want to learn more or edit this definition?
Click here to read more!